<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47114">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02130427</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 08909</org_study_id>
    <nct_id>NCT02130427</nct_id>
  </id_info>
  <brief_title>A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy</brief_title>
  <official_title>A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will determine changes over time in tumor volume/motion &amp; patient anatomy,
      as well as dose distributions to normal organs. The study will inform medical
      decision-making about need for (and timing of) re-calibration of radiation dosimetry plans.
      Weekly CT and/or serial MR scans will be employed for those patients receiving 7-8 wks of
      radiation therapy. The study will enroll 30 patients in each stratum: Non small cell lung
      cancer (NSCLC), Head &amp; Neck, gastrointestinal (GI) and Gynecologic tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>4-6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Biopsy Proven Non Small Cell Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Rectal Cancers</condition>
  <condition>Gynecological Malignancy Requiring Definitive Radiotherapy</condition>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Head &amp; Neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gynecologic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>NSCLC</arm_group_label>
    <arm_group_label>Head &amp; Neck</arm_group_label>
    <arm_group_label>GI</arm_group_label>
    <arm_group_label>Gynecologic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 and above.

          -  Biopsy proven diagnosis of non-small cell lung cancer, small cell lung cancer, head
             and neck, esophageal, gastric, pancreatic, anal, hepatic, biliary, colorectal,
             cervical, endometrial, vaginal, vulvar, ovarian cancer and any other gastrointestinal
             or gynecological cancers requiring definitive radiotherapy alone with or without
             concurrent chemotherapy.

          -  Able to provide written informed consent and comply with all study procedures.

          -  Entire course of radiotherapy will be delivered at the University of Pennsylvania
             Perelman Center for Advanced Medicine.

        Exclusion Criteria:

        - Pregnancy or women of childbearing potential and men who are sexually active and not
        willing/able to use medically acceptable forms of contraception; this exclusion is
        necessary because the treatment involved in this study may be significantly teratogenic.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Simone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Simone, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Simone, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Charles Simone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult subjects</keyword>
  <keyword>NSCLC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
